Latest Posts

Tag: Sosei Group Corporation

Teva invested $10M in Heptares Therapeutics

A licensing and drug-discovery agreement with UK-based Heptares Therapeutics, a unit of Sosei Group Corporation under which it will receive exclusive global rights to develop, manufacture and commercialize small-molecule calcitonin gene-related peptide (CGRP) antagonists for the treatment of migraine headaches, was signed by Israeli pharmaceutical giant Teva.┬áBased on this agreement, Heptares will receive a payment-investment […]

Keep Reading
Go to TOP